Last reviewed · How we verify
Intramuscular ziprasidone mesylate
Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.
Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Acute agitation associated with schizophrenia or bipolar disorder, Schizophrenia (maintenance and acute treatment), Bipolar disorder (acute mania and maintenance).
At a glance
| Generic name | Intramuscular ziprasidone mesylate |
|---|---|
| Also known as | Zeldox, Geodon |
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Ziprasidone mesylate is the salt form of ziprasidone designed for intramuscular injection, providing rapid onset of action for acute agitation or psychotic symptoms. By antagonizing dopamine D2 receptors and serotonin 5-HT2A receptors, it reduces positive symptoms of psychosis and agitation while the serotonergic activity may help mitigate extrapyramidal side effects. The intramuscular formulation allows for faster therapeutic effect compared to oral administration.
Approved indications
- Acute agitation associated with schizophrenia or bipolar disorder
- Schizophrenia (maintenance and acute treatment)
- Bipolar disorder (acute mania and maintenance)
Common side effects
- Injection site pain
- Headache
- Dizziness
- Akathisia
- Extrapyramidal symptoms
- Somnolence
- QT prolongation
Key clinical trials
- A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation (PHASE3)
- A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder (PHASE4)
- A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis (PHASE4)
- Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation
- Ziprasidone vs Standard Therapy for Agitated Patients in the ED (PHASE4)
- The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation (PHASE4)
- Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: